GlassScriptPhysician profile
Marwan I Shuayto
NPI 1841383924
$23,554.58
in general payments reported to CMS, 2019-2025
62 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $1,373 · 2021: $8,491 · 2022: $5,530 · 2023: $1,690 · 2024: $1,706 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,271 · Consulting Fee: $975 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,270.60 |
| Consulting Fee | $975.00 |
| Education | $117.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,692.93 | 2019-2025 | Wavewriter Alpha Prime 16, General - Dbs, Vercise |
| Abbott Laboratories | $2,621.20 | 2019-2025 | Proclaim, Eterna |
| Nalu Medical, INC. | $2,006.63 | 2022-2024 | Nalu Neurostimulation System |
| Livanova USA, INC. | $1,720.79 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,635.62 | 2019-2025 | |
| Abbvie INC. | $1,177.30 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Allergan, INC. | $566.51 | 2019-2022 | |
| Biogen, INC. | $556.02 | 2019-2025 | Tysabri, Skyclarys |
| Emd Serono, INC. | $551.55 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $477.40 | 2019-2022 | |
| Horizon Therapeutics Plc | $440.09 | 2021-2023 | Uplizna |
| Celgene Corporation | $433.66 | 2021-2025 | Zeposia |
| Amgen INC. | $399.09 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $302.10 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $291.78 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Shuayto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.